文献速递认知障碍与痴呆

后皮质萎缩的人口学、临床、生物标志物与神经病理学关联:一项国际队列研究与个体参与者数据荟萃分析

Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis.
PubMed 文献 · Lancet Neurol · 2024-01-01

该国际队列与个体参与者数据荟萃分析纳入16国36个中心的1092例后皮质萎缩患者,发现平均起病年龄59.4岁,80%为纯综合征型,尸检145例中94%为阿尔茨海默病病理,淀粉样蛋白PET阳性率94%、tau-PET阳性率97%,提示该综合征对阿尔茨海默病病理具有高度特异性。

要点

  • 后皮质萎缩平均起病年龄59.4岁,80%表现为纯综合征型。
  • 尸检145例中94%为阿尔茨海默病病理,常见共病理包括脑淀粉样血管病71%、路易体病44%、脑血管损伤42%。
  • 淀粉样蛋白PET阳性率94%、tau-PET阳性率97%,脑脊液淀粉样蛋白β阳性率81%、磷酸化tau阳性率65%。

核心结论

  • 后皮质萎缩通常表现为纯的、早发性痴呆综合征,对 underlying 阿尔茨海默病病理具有高度特异性。
  • 需进一步研究以了解性别、遗传、病前认知强弱及脑网络完整性的贡献,从而理解认知易感性和进展率的驱动因素。

研究设计与样本

  • 检索PubMed自建库至2021年8月1日发表的后皮质萎缩相关研究,从这些研究中识别研究中心并索取首次诊断访视时获取的脱敏个体参与者数据(已发表和未发表)。
  • 纳入标准为当地中心定义的后皮质萎缩临床诊断且具备阿尔茨海默病生物标志物(PET或脑脊液)可用性,或尸检诊断;并非所有个体均符合共识标准,部分使用中心特定流程或在共识标准制定前诊断。
  • 从1353篇论文中识别55个研究中心,29个中心回应请求,另通过阿尔茨海默病协会广告招募7个中心,最终获得16个国家36个研究中心1092例个体的数据。

主要发现

  • 症状起病平均年龄59.4岁(95%CI 58.9-59.8;I²=77%),女性占60%(56-64;I²=35%),纯综合征型占80%(72-89;I²=98%)。
  • 脑脊液淀粉样蛋白β(536例来自28个中心)阳性率81%(95%CI 75-87;I²=78%),脑脊液磷酸化tau(503例来自29个中心)阳性率65%(56-75;I²=87%)。
  • 淀粉样蛋白PET(299例来自24个中心)阳性率94%(95%CI 90-97;I²=15%),tau-PET(170例来自13个中心)阳性率97%(93-100;I²=12%)。
  • 尸检(145例来自13个中心)中最常见神经病理诊断为阿尔茨海默病(94%,95%CI 90-97;I²=0%),常见共病理为脑淀粉样血管病(71%,54-88;I²=89%)、路易体病(44%,25-62;I²=77%)和脑血管损伤(42%,24-60;I²=88%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Posterior cortical atrophy is a rare syndrome characterised by early, prominent, and progressive impairment in visuoperceptual and visuospatial processing. The disorder has been associated with underlying neuropathological features of Alzheimer's disease, but large-scale biomarker and neuropathological studies are scarce. We aimed to describe demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy in a large international cohort. METHODS: We searched PubMed between database inception and Aug 1, 2021, for all published research studies on posterior cortical atrophy and related terms. We identified research centres from these studies and requested deidentified, individual participant data (published and unpublished) that had been obtained at the first diagnostic visit from the corresponding authors of the studies or heads of the research centres. Inclusion criteria were a clinical diagnosis of posterior cortical atrophy as defined by the local centre and availability of Alzheimer's disease biomarkers (PET or CSF), or a diagnosis made at autopsy. Not all individuals with posterior cortical atrophy fulfilled consensus criteria, being diagnosed using centre-specific procedures or before development of consensus criteria. We obtained demographic, clinical, biofluid, neuroimaging, and neuropathological data. Mean values for continuous variables were combined using the inverse variance meta-analysis method; only research centres with more than one participant for a variable were included. Pooled proportions were calculated for binary variables using a restricted maximum likelihood model. Heterogeneity was quantified using I2. FINDINGS: We identified 55 research centres from 1353 papers, with 29 centres responding to our request. An additional seven centres were recruited by advertising via the Alzheimer's Association. We obtained data for 1092 individuals who were evaluated at 36 research centres in 16 countries, the other sites having not responded to our initial invitation to participate to the study. Mean age at symptom onset was 59·4 years (95% CI 58·9-59·8; I2=77%), 60% (56-64; I2=35%) were women, and 80% (72-89; I2=98%) presented with posterior cortical atrophy pure syndrome. Amyloid β in CSF (536 participants from 28 centres) was positive in 81% (95% CI 75-87; I2=78%), whereas phosphorylated tau in CSF (503 participants from 29 centres) was positive in 65% (56-75; I2=87%). Amyloid-PET (299 participants from 24 centres) was positive in 94% (95% CI 90-97; I2=15%), whereas tau-PET (170 participants from 13 centres) was positive in 97% (93-100; I2=12%). At autopsy (145 participants from 13 centres), the most frequent neuropathological diagnosis was Alzheimer's disease (94%, 95% CI 90-97; I2=0%), with common co-pathologies of cerebral amyloid angiopathy (71%, 54-88; I2=89%), Lewy body disease (44%, 25-62; I2=77%), and cerebrovascular injury (42%, 24-60; I2=88%). INTERPRETATION: These data indicate that posterior cortical atrophy typically presents as a pure, young-onset dementia syndrome that is highly specific for underlying Alzheimer's disease pathology. Further work is needed to understand what drives cognitive vulnerability and progression rates by investigating the contribution of sex, genetics, premorbid cognitive strengths and weaknesses, and brain network integrity. FUNDING: None.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Chapleau M, La Joie R, Yong K, et al. Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis. Lancet Neurol. 2024. PMID: 38267189. doi:10.1016/S1474-4422(23)00414-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。